Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study

• Main Authors: Jean Marc Steens, Didier Scherrer, Paul Gineste, P. Noel Barrett, Supparatpino Khuanchai, Ratanasuwan Winai, Kiat Ruxrungtham, Jamal Tazi, Robert Murphy, Hartmut Ehrlich
• Format: Journal
• Published: 2018
• Subjects: Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021658372&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/57674
• Institution: Chiang Mai University

Copyright © 2017 Steens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism of viral replication inhibition. This was...